Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases

Z Li, L Wang, Y Ren, Y Huang, W Liu, Z Lv, L Qian… - Cell Death …, 2022 - nature.com
Arginase, a binuclear manganese metalloenzyme in the urea, catalyzes the hydrolysis of L-
arginine to urea and L-ornithine. Both isoforms, arginase 1 and arginase 2 perform …

Red blood cell dysfunction: a new player in cardiovascular disease

J Pernow, A Mahdi, J Yang, Z Zhou - Cardiovascular research, 2019 - academic.oup.com
The primary role of red blood cells (RBCs) is to transport oxygen to the tissues and carbon
dioxide to the lungs. However, emerging evidence suggests an important role of the RBC …

Endothelial dysfunction due to eNOS uncoupling: Molecular mechanisms as potential therapeutic targets

A Janaszak-Jasiecka, A Płoska, JM Wierońska… - Cellular & molecular …, 2023 - Springer
Nitric oxide (NO) is one of the most important molecules released by endothelial cells, and
its antiatherogenic properties support cardiovascular homeostasis. Diminished NO …

Red blood cell peroxynitrite causes endothelial dysfunction in type 2 diabetes mellitus via arginase

A Mahdi, J Tengbom, M Alvarsson, B Wernly, Z Zhou… - Cells, 2020 - mdpi.com
We recently showed that red blood cells (RBCs) from patients with type 2 diabetes mellitus
(T2DM-RBCs) induce endothelial dysfunction through a mechanism involving arginase I and …

Improvement in endothelial function in cardiovascular disease-Is arginase the target?

A Mahdi, O Kövamees, J Pernow - International journal of cardiology, 2020 - Elsevier
Endothelial dysfunction represents an early change in the vascular wall in areas prone to
atherosclerotic plaque formation and is present in association with several risk factors for …

Arginase-1 deletion in erythrocytes promotes vascular calcification via enhanced GSNOR (S-nitrosoglutathione reductase) expression and NO signaling in smooth …

R Gogiraju, L Renner, ML Bochenek… - … and Vascular Biology, 2022 - Am Heart Assoc
Background: Erythrocytes (red blood cells) participate in the control of vascular NO
bioavailability. The purpose of this study was to determine whether and how genetic deletion …

Exogenous NO therapy for the treatment and prevention of atherosclerosis

T Gori - International Journal of Molecular Sciences, 2020 - mdpi.com
Amyl nitrite was introduced in 1867 as the first molecule of a new class of agents for the
treatment of angina pectoris. In the following 150 years, the nitric oxide pathway has been …

Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis

A Gamrat, MA Surdacki, B Chyrchel… - Journal of Clinical …, 2020 - mdpi.com
Endothelial dysfunction, associated with depressed nitric oxide (NO) bioavailability, is a well-
recognized contributor to both accelerated atherogenesis and microvascular complications …

Whole blood viscosity is associated with baseline cerebral perfusion in acute ischemic stroke

P Gyawali, TP Lillicrap, S Tomari, A Bivard… - Neurological …, 2022 - Springer
Whole blood viscosity (WBV) is the intrinsic resistance to flow developed due to the frictional
force between adjacent layers of flowing blood. Elevated WBV is an independent risk factor …

High output heart failure in multiple myeloma: pathogenetic considerations

M Carlisi, S Mancuso, R Lo Presti, S Siragusa, G Caimi - Cancers, 2022 - mdpi.com
Simple Summary Multiple myeloma is a plasma cell disorder that accounts for around 10%
of all haematological malignancies. This neoplasia is often associated with a significant …